Gilead Sciences, Inc. (GILD) Stock Analysis
Temp Headwind edge
Healthcare · Drug Manufacturers - General
Hold if already holding. Not a fresh buy at $128.50, but acceptable to hold if already in. Reasons: Concentration risk — Customer: Cardinal Health, Cencora, McKesson (90.0%); Concentration risk — Product: HIV.
Gilead Sciences is a biopharmaceutical company with 25+ commercial products across HIV (Biktarvy, Descovy), viral hepatitis (Epclusa, Vemlidy), and oncology (Yescarta, Trodelvy), operating in 35+ countries. HIV products generate a substantial portion of revenue, distributed... Read more
Hold if already holding. Not a fresh buy at $128.50, but acceptable to hold if already in. Reasons: Concentration risk — Customer: Cardinal Health, Cencora, McKesson (90.0%); Concentration risk — Product: HIV. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 6.3/10, moderate confidence.
Passes 4/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: conservative.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerCardinal Health, Cencora, McKesson90%10-K Item 1A: 'approximately 90% of our gross product sales in the U.S. have been to three wholesalers—Cardinal Health, Inc., Cencora, Inc. and McKesson Corporation'
- HIGHProductHIV10-K Item 1A: 'We receive a substantial portion of our revenue from sales of our products for the treatment and prevention of HIV infection'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $128.50, but acceptable to hold if already in. Reasons: Concentration risk — Customer: Cardinal Health, Cencora, McKesson (90.0%); Concentration risk — Product: HIV. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $142.52 (+10.9%), stop $123.81 (−3.8%), A.R:R 2.1:1. Score 6.3/10, moderate confidence.
Take-profit target: $142.52 (+10.6% upside). Target $142.52 (+10.9%), stop $123.81 (−3.8%), A.R:R 2.1:1. Stop-loss: $123.81.
Concentration risk — Customer: Cardinal Health, Cencora, McKesson (90.0%); Concentration risk — Product: HIV; Leverage penalty (D/E 1.1): -0.5.
Gilead Sciences, Inc. trades at a P/E of 19.0 (forward 13.4). TrendMatrix value score: 7.3/10. Verdict: Hold.
39 analysts cover GILD with a consensus score of 4.1/5. Average price target: $158.
What does Gilead Sciences, Inc. do?Gilead Sciences is a biopharmaceutical company with 25+ commercial products across HIV (Biktarvy, Descovy), viral...
Gilead Sciences is a biopharmaceutical company with 25+ commercial products across HIV (Biktarvy, Descovy), viral hepatitis (Epclusa, Vemlidy), and oncology (Yescarta, Trodelvy), operating in 35+ countries. HIV products generate a substantial portion of revenue, distributed primarily through three U.S. wholesalers (Cardinal Health, Cencora, McKesson).